25.06 14:28 | dpa-AFX: AbbVie: FDA Issues CRL For ABBV-951 |
25.06 14:17 | dpa-AFX: *ABBVIE RECEIVES FDA COMPLETE RESPONSE LETTER FOR ABBV-951 IN PARKINSON'S DISEASE TREATMENT |
21.06 14:03 | dpa-AFX: *ABBVIE (ABBV) DECLARES QUARTERLY DIVIDEND OF $ 1.55, RECORD DATE 7/15/2024 |
21.06 14:02 | dpa-AFX: *ABBVIE DECLARES QUARTERLY CASH DIVIDEND OF $1.55/SHR; PAYABLE AUGUST 15/RECORD JULY 15 |
20.06 14:02 | dpa-AFX: *ABBVIE APPOINTS ROXANNE S. AUSTIN AS LEAD INDEPENDENT DIRECTOR, EFFECTIVE JULY 1 |
19.06 07:26 | dpa-AFX: AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis |
13.06 14:31 | dpa-AFX: AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 |
13.06 14:02 | dpa-AFX: *ABBVIE AND FUTUREGEN STRIKE $1.71 BLN DEAL TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
13.06 14:00 | dpa-AFX: *ABBVIE, FUTUREGEN TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
12.06 15:02 | dpa-AFX: AbbVie To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:00 AM ET |
06.06 15:34 | dpa-AFX: AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC |
06.06 14:47 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER |
05.06 15:02 | dpa-AFX: *ABBVIE SAYS FIRST PATIENT TREATED WITH INVESTIGATIONAL ABBV-383 IN CERVINO PHASE 3 STUDY |
05.06 06:32 | dpa-AFX: *HSBC HEBT ABBVIE AUF 'BUY' - ZIEL 185 USD |
05.06 06:32 | dpa-AFX: *HSBC RAISES ABBVIE TO 'BUY' - PRICE TARGET 185 USD |
04.06 15:00 | dpa-AFX: AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients |
04.06 14:42 | dpa-AFX: *ABBV : RINVOQ AVAILABLE FOR PEDIATRIC PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS &PSORIATIC ARTHRITIS |
31.05 08:45 | dpa-AFX: AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis |
31.05 08:24 | dpa-AFX: *ABBVIE'S RISANKIZUMAB RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS |
28.05 14:04 | dpa-AFX: *ABBVIE SHOWCASES ROBUST SOLID TUMOR PIPELINE AT ASCO 2024, WITH NEW DATA FROM ADC PLATFORM |
|